Literature DB >> 25060431

Pharmacology: a new bleeding issue.

A N Robinson, C Scully.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25060431     DOI: 10.1038/sj.bdj.2014.602

Source DB:  PubMed          Journal:  Br Dent J        ISSN: 0007-0610            Impact factor:   1.626


× No keyword cloud information.
  5 in total

1.  Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.

Authors:  Teddy Kosoglou; Larisa Reyderman; Renger G Tiessen; André A van Vliet; Robert R Fales; Robert Keller; Bo Yang; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2011-09-21       Impact factor: 2.953

2.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Authors:  Pierluigi Tricoci; Zhen Huang; Claes Held; David J Moliterno; Paul W Armstrong; Frans Van de Werf; Harvey D White; Philip E Aylward; Lars Wallentin; Edmond Chen; Yuliya Lokhnygina; Jinglan Pei; Sergio Leonardi; Tyrus L Rorick; Ann M Kilian; Lisa H K Jennings; Giuseppe Ambrosio; Christoph Bode; Angel Cequier; Jan H Cornel; Rafael Diaz; Aycan Erkan; Kurt Huber; Michael P Hudson; Lixin Jiang; J Wouter Jukema; Basil S Lewis; A Michael Lincoff; Gilles Montalescot; José Carlos Nicolau; Hisao Ogawa; Matthias Pfisterer; Juan Carlos Prieto; Witold Ruzyllo; Peter R Sinnaeve; Robert F Storey; Marco Valgimigli; David J Whellan; Petr Widimsky; John Strony; Robert A Harrington; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

Review 3.  Novel anti-platelet agents: focus on thrombin receptor antagonists.

Authors:  Flavio de Souza Brito; Pierluigi Tricoci
Journal:  J Cardiovasc Transl Res       Date:  2013-02-22       Impact factor: 4.132

4.  Vorapaxar in the secondary prevention of atherothrombotic events.

Authors:  David A Morrow; Eugene Braunwald; Marc P Bonaca; Sebastian F Ameriso; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; Stephen D Wiviott; John Strony; Sabina A Murphy
Journal:  N Engl J Med       Date:  2012-03-24       Impact factor: 91.245

5.  Efficacy and safety of vorapaxar in patients with prior ischemic stroke.

Authors:  David A Morrow; Mark J Alberts; Jay P Mohr; Sebastian F Ameriso; Marc P Bonaca; Shinya Goto; Graeme J Hankey; Sabina A Murphy; Benjamin M Scirica; Eugene Braunwald
Journal:  Stroke       Date:  2013-02-08       Impact factor: 7.914

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.